首页> 外文期刊>Gynecologic Oncology: An International Journal >CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes
【24h】

CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes

机译:高级浆液卵巢癌中的CCNE1和BRD4共同扩增与临床结果不佳相关

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. High-grade serous ovarian cancer (HGSOC) is the most common and lethal histological subtype of epithelial ovarian cancer. HGSOC with cyclin E1 gene (CCNE1) amplification and bromodomain and extraterminal 4 (BRD4) amplification have been associated with poor outcomes. Our objective was to evaluate clinical outcomes of HGSOC with co-amplification of CCNE1 and BRD4 and high protein expression of cyclin E and BRD4.
机译:客观的。 高级浆液卵巢癌(HGSOC)是上皮性卵巢癌中最常见和最致命的组织学亚型。 HGSOC具有细胞周期蛋白E1基因(CCNE1)扩增和溴琼瘤和氨纶4(BRD4)扩增已与差的结果有关。 我们的目的是评估Hgsoc的临床结果,通过CCNE1和BRD4的共同扩增和细胞周期蛋白E和BRD4的高蛋白质表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号